Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 764

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 764
---
 |
| Exercise of warrants                                                                  |     |                       — |   |     |      — |   |     |  1,146 |   |
| Receipt of a convertible loan from shareholders                                       |     |                     450 |   |     |  1,242 |   |     |      — |   |
| Net cash provided by financing activities                                             |     |                      89 |   |     |  2,401 |   |     |  1,110 |   |
| Exchange rate differences on balances of cash and cash equivalents                    |     |                     (41 | ) |     |   (166 | ) |     |   (634 | ) |
| Decrease in cash and cash equivalents                                                 |     |                    (496 | ) |     |   (670 | ) |     | (5,680 | ) |
| Cash and cash equivalents at the beginning of the year                                |     |                   1,146 |   |     |  1,816 |   |     |  7,490 |   |
| Cash and cash equivalents at the end of the year                                      |     |                     650 |   |     |  1,146 |   |     |  1,810 |   |
| Material non-cash transactions                                                        |     |                         |   |     |        |   |     |        |   |
| Right-of-use asset recognized with corresponding lease liability                      |     |                       — |   |     |      — |   |     |    842 |   |

The attached Notes constitute an integral part of the financial statements.

Annex G-7 KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 1: — General A. General description of the company and its activity: Kadimastem Ltd. (hereinafter, the “Company”) was incorporated in Israel on October 6, 2008, and began its business activities on August 27, 2009. On June 6, 2013, the Company completed a public offering of its shares on the Tel Aviv Stock Exchange (“TASE”). The Company’s offices are located in Ness Ziona, Israel. The Company is engaged in the development of drugs for the treatment of terminal muscular dystrophy (also known as ALS) and diabetes in the field of regenerative medicine. B.As of December 31, 2024, the Company’s capital deficiency, accumulated deficit, and negative working capital amounted to USD $